Tadalista 10 mg, like other Tadalafil products, is a generic version of Cialis, which was originally approved by the U.S. Food and Drug Administration (FDA) in 2003. Tadalista 10 mg is a generic formulation, meaning it was introduced after the patent for Cialis expired, allowing other manufacturers to produce Tadalafil under different brand names at a more affordable price. The exact approval date of Tadalista 10 mg by health authorities (like the FDA or equivalent regulatory bodies in other countries) can vary by the specific country and the manufacturer. However, since Tadalista is a generic version of Cialis, its approval would have occurred sometime after Cialis's patent expired in 2017 when generics for tadalafil began to be widely available. Timeline: Cialis (Tadalafil) was first approved by the FDA in 2003. Tadalista, as a generic version of Tadalafil, began to be sold around 2018-2019 in many markets, as the patent for Cialis expired in 2017 and generics became available soon after. Thus, Tadalista 10 mg likely received its approval from health authorities shortly after 2017, when the patent for Cialis expired. The approval process for generics is typically quicker than for brand-name drugs, especially when the active ingredient is already well established, as in the case of Tadalafil.